曹飞要约收购济川药业，二季度持续督导情况良好

Group 1 - The core viewpoint of the article is that Cao Fei's acquisition of Hubei Jichuan Pharmaceutical has been completed, with a significant shareholding established [1] - The acquisition triggered a mandatory tender offer obligation, with the offer period running from June 11 to July 17, 2025 [1] - As of August 1, the transfer of shares was completed, resulting in Cao Fei and his concerted parties controlling 61.15% of the company [1] Group 2 - The tender offer involved 16,300 shares, representing 0.0018% of the total share capital [1] - During the ongoing supervision period, the acquirer and the listed company operated in a compliant manner, with no major adjustments proposed to the company's main business, assets, or personnel [1] - There were no violations regarding guarantees or borrowings reported by Jichuan Pharmaceutical [1]